Fluad consists of an inactivated, subunit trivalent influenza virus antigen produced in eggs and an oil-in-water emulsion adjuvant, MF59C.1.
Fluad is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
Fluad is administered as a single 0.5 mL intramuscular injection in adults 65 years of age and older.
Fluad helps protect against the same flu strains as other seasonal flu shots, but it has something they don’t have: an immune-enhancing ingredient that can help provide a strong immune response to the flu in adults 65 and older.
Fluad is the first FDA-approved seasonal flu shot that contains an adjuvant, which is an immune-enhancing ingredient.
The immune-enhancing ingredient in Fluad is an oil derived from squalene. Squalene is a naturally occurring substance found in humans, animals, and plants.
Adults aged 65 and older who have an aging immune system might have a lower immune response to traditional flu vaccines compared to younger adults.
Squalene the immune-enhancing ingredient is proven to provide a strong immune response to help the immune systems of adults 65 and older to recognize and respond to the flu virus.
On November 24, 2015, the U.S. Food and Drug Administration sent an approval letter authorizing the introduction or delivery of Fluad into interstate commerce.